{"result": "(\"entity\"<|>MELMED S<|>PERSON<|>Melmed S is an author of the Williams Textbook of Endocrinology, which discusses various aspects of endocrinology and osteoporosis treatment.)\n##\n(\"entity\"<|>POLONSKY KS<|>PERSON<|>Polonsky KS is a co-author of the Williams Textbook of Endocrinology, contributing to the understanding of endocrine disorders.)\n##\n(\"entity\"<|>REED LARSEN P<|>PERSON<|>Reed Larsen P is a co-author of the Williams Textbook of Endocrinology, providing insights into hormonal treatments and their effects.)\n##\n(\"entity\"<|>KRONENBERG HM<|>PERSON<|>Kronenberg HM is a co-author of the Williams Textbook of Endocrinology, focusing on endocrine system diseases and treatments.)\n##\n(\"entity\"<|>UPTODATE INC<|>ORGANIZATION<|>UpToDate Inc. is a clinical decision support resource that provides evidence-based information on various medical topics, including osteoporosis.)\n##\n(\"entity\"<|>WALTHAM<|>GEO<|>Waltham is a city in Massachusetts, USA, where UpToDate Inc. is located.)\n##\n(\"entity\"<|>OSTEOPOROSIS<|>EVENT<|>Osteoporosis is a medical condition characterized by weakened bones, increasing the risk of fractures, often discussed in the context of glucocorticoid treatment.)\n##\n(\"entity\"<|>GLUCOCORTICOIDS<|>EVENT<|>Glucocorticoids are a class of steroid hormones that can lead to osteoporosis as a side effect when used for treatment.)\n##\n(\"relationship\"<|>MELMED S<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>Melmed S is a co-author of the Williams Textbook of Endocrinology, which discusses osteoporosis and its management<|>8)\n##\n(\"relationship\"<|>POLONSKY KS<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>Polonsky KS is a co-author of the Williams Textbook of Endocrinology, contributing to the understanding of osteoporosis<|>8)\n##\n(\"relationship\"<|>REED LARSEN P<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>Reed Larsen P is a co-author of the Williams Textbook of Endocrinology, which includes information on osteoporosis<|>8)\n##\n(\"relationship\"<|>KRONENBERG HM<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>Kronenberg HM is a co-author of the Williams Textbook of Endocrinology, focusing on osteoporosis treatment<|>8)\n##\n(\"relationship\"<|>UPTODATE INC<|>WALTHAM<|>UpToDate Inc. is located in Waltham, Massachusetts, providing medical information<|>7)\n##\n(\"relationship\"<|>GLUCOCORTICOIDS<|>OSTEOPOROSIS<|>Glucocorticoids are known to cause osteoporosis as a side effect of their use<|>9)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: apoptosis\n         mama. La concentración de colesterol en lipoproteínas de densidad baja disminuye tam-                                                  también puede explicar la tendencia de los glucocorticoides a causar osteonecrosis.\n         bién en pacientes que reciben este tratamiento.                                                                                        Además, los glucocorticoides alteran la dinámica secretora de la PTH (reducen la secreción\n         El raloxifeno aumenta ligeramente la DMO vertebral y baja un 40% el riesgo de fractura                                                 tónica y aumentan la cantidad liberada como pulsos), antagonizan la acción anabólica de\n         vertebral, pero no modifica el riesgo de fractura no vertebral.                                                                        la PTH e inhiben la producción del IGF-1 y testosterona. La reducción en la formación\n         El ranelato de estroncio estimula la absorción ósea de calcio e inhibe la resorción ósea. En                                           ósea se asocia con una disminución en la tasa de aposición de minerales y en los marcado-\n         mujeres posmenopáusicas con                  enfermedad confirmada,             disminuyó un 40% el riesgo de                          res bioquímicos de formación ósea en suero y orina.\n         fracturas vertebrales. Datos recientes indican un aumento de los episodios cardiovascu-                                                Referencias:\n         lares en mujeres tratadas con estroncio.                                                                                               • Melmed S, Polonsky KS, Reed Larsen P, Kronenberg HM. Williams Textbook of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016.\n                                                                                                                                                • Rosen HN. Clinical features and evaluation of glucocorticoid-induced osteoporosis. Rosen CJ, ed. UptoDate. Waltham, MA: UpToDate Inc.\n         Los osteoclastos tienen receptores de calcitonina y la calcitonina puede inhibir rápidamen-                                              https://www.uptodate.com (acceso 11 de junio de 2019).\n                                                                                                                                                • Rosen HN, Saag KG. Prevention and treatment of glucocorticoid-induced osteoporosis. Rosen CJ, ed. UptoDate. Waltham, MA:\n         te la resorción ósea. En mujeres con osteoporosis posmenopáusica, la calcitonina nasal en                                                UpToDate Inc. https://www.uptodate.com (acceso 11 de junio de 2019).\n         dosis de 200 UI/día bajó una tercera parte la incidencia de fractura vertebral.\n         Referencias:                                                                                                                           En la osteoporosis esteroidea, señale la respuesta falsa:\n         • Melmed S, Polonsky KS, Reed Larsen P, Kronenberg HM. Williams Textbook of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016.  23\n         • Rosen HN. The use of bisphosphonates in postmenopausal women with osteoporosis. Rosen CJ, Schmader KE, eds. UptoDate.\n           Waltham, MA: UpToDate Inc. https://www.uptodate.com (acceso 11 de junio de 2019).                                                    A. Dosis desde 5 mg al día de prednisona pueden ocasionar incremento de fracturas.\n         • Rosen HN, Drezner MK. Overview of the management of osteoporosis in postmenopausal women. Rosen CJ, Schmader KE, eds.\n           UptoDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com (acceso 11 de junio de 2019).                                          B. La pérdida de hueso es predominante en hueso cortical.\n                                                                                                                                                C. El efecto de los corticoides sobre el hueso es fundamentalmente dosis y tiempo\n                                                                                                                                                    dependiente.\n     22  En la osteoporosis secundaria a glucocorticoides, indique cuál de las siguientes                                                       D.  Los glucocorticoides disminuyen la absorción intestinal de calcio.\n         afirmaciones es falsa:\n         A. Existe una inhibición de la absorción del calcio por alteración de la producción                                                    COMENTARIO\n             de 1,25(OH)2D.3\n         B. Los glucocorticoides suprimen la expresión de IGF-1 en las células óseas.                                                           La terapia con glucocorticoides es la causa más frecuente de osteoporosis secundaria.\n         C. El hueso más afectado es el trabecular.                                                                                             El hueso trabecular es el más afectado y la DMO vertebral es el indicador más sensible de\n                                                                                                                                                la pérdida ósea (opción B falsa: respuesta correcta). Los marcadores de recambio óseo no\n         D.  Los marcadores de resorción ósea son muy útiles en el seguimiento de estos pacientes.                                              son útiles en el tratamiento de estos pacientes.\n                                                                                                                                                El efecto es dosis y tiempo dependiente y se produce a partir de dosis tan pequeñas como\n         COMENTARIO                                                                                                                             2,5 mg/día de prednisona o equivalente.\n         El hueso trabecular es el más afectado y la DMO vertebral es el indicador más sensible                                                 Los glucocorticoides disminuyen la\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}